Head to Head Comparison: Inogen (NASDAQ:INGN) & CONMED (NYSE:CNMD)

Inogen (NASDAQ:INGN – Get Free Report) and CONMED (NYSE:CNMD – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.

Insider and Institutional Ownership

89.9% of Inogen shares are owned by institutional investors. 2.5% of Inogen shares are owned by company insiders. Comparatively, 0.3% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Inogen and CONMED, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inogen 1 0 0 1 2.50
CONMED 1 7 0 0 1.88

CONMED has a consensus price target of $44.00, suggesting a potential downside of 12.26%. Given CONMED’s higher probable upside, analysts plainly believe CONMED is more favorable than Inogen.

Profitability

This table compares Inogen and CONMED’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inogen -10.46% -19.29% -12.02%
CONMED 5.36% 13.93% 6.26%

Volatility & Risk

Inogen has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, CONMED has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Valuation and Earnings

This table compares Inogen and CONMED”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inogen $348.67 million 0.42 -$22.75 million ($1.31) -4.30
CONMED $1.37 billion 1.09 $47.06 million $2.42 20.72

CONMED has higher revenue and earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Summary

CONMED beats Inogen on 9 of the 14 factors compared between the two stocks.

About Inogen

(Get Free Report)

Inogen, Inc. is a medical technology company focused on respiratory care. It develops, manufactures and markets oxygen concentrators and related products for people who require supplemental oxygen, including those with chronic respiratory conditions. Its products include the Inogen One line of portable oxygen concentrators, stationary oxygen concentrators and accessories. The company sells through direct-to-consumer channels and healthcare providers. Founded in 2001 and headquartered in Goleta, California, Inogen serves customers in the United States and international markets.

About CONMED

(Get Free Report)

CONMED Corporation is a medical technology company that develops and markets devices and equipment for orthopedic and general surgery. Its products support minimally invasive procedures and include arthroscopy systems, powered surgical instruments, electrosurgical equipment, and endoscopic technologies. The company was founded in 1970 and serves hospitals, surgery centers, and other healthcare providers. Its products are sold in the United States and internationally.

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.